Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06593431 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial

StatusRecruiting
PhasePhase 3
Started2024-10-23
View on ClinicalTrials.gov ↗

Amendment history

2026-07-24
Study Status, Contacts/Locations v6
Study sites3→4
2026-05-18
Study Status, Contacts/Locations v5
Study sites1→3
2026-04-13
2 amendments v3-v4
2 re-verifications since 2025-10-20, no change to tracked fields
2025-04-10
Study Identification, Study Status, Oversight, Eligibility, Contacts/Locations v2
Eligibility criteria+40 characters
Inclusion Criteria: Age 18 Histologically or cytologically confirmed stage IV pancreatic ductal adenocarcinoma. Histologic / cytologic con [...] ogical/pathologic confirmation of distant metastatic disease is not required if clinical and radiographic consensus is that the patient [...] nt, etc.). In the event of ambiguity or equivocal findings, athe studyprincipal investigator or co-Investigatorprincipal investigator will make a final determination of whether criteria are met [...] se adequate contraception for the duration of the study and 36 monthmonths after the last dose of study medication. Adequate contrace [...]
Study sitescontacts updated at 1 of 1 site
Study titlerevised
Extending Outcomes for Pancreas Cancer Patients withWith Nominal Oligometastatic Disease (EXPAND): aA Randomized Phase III Trial
2025-01-27
Not Yet Recruiting→Recruiting Study Status, Oversight, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2024-12-31→confirmed 2024-10-23
Study sitesdetails revised at 1 of 1 site
2024-09-09
Original filing
The EXPAND trial (EXtending outcomes for PAncreas cancer patients with Nominal oligometastatic Disease) is a randomized phase III trial assessing the efficacy of MDT to improve PFS and OS for patients with oligometastatic pancreatic ductal adenocarcinoma (PDAC).
Trial Details
NCT Number NCT06593431
Lead Sponsor M.D. Anderson Cancer Center
Conditions Pancreas Cancer, Oligometastatic
Enrollment 80 participants
Start Date 2024-10-23
Primary Completion 2029-06-29 (estimated)
Study Completion 2029-06-29 (estimated)
Updated on ClinicalTrials.gov 2026-07-27